文献速递慢性肾脏病血液净化与透析

肾癌外科治疗后的终末期肾病

End-Stage Kidney Disease following Surgical Management of Kidney Cancer.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-09-28

该研究基于澳大利亚昆士兰癌症登记数据,纳入2009至2014年2739例新诊断肾癌患者,分析术后ESKD发生率及全澳肾脏替代治疗趋势。结果显示ESKD发生率为4.9/1000人年,根治性肾切除和部分肾切除后3年累积发生率分别为1.9%和1.0%,且1995至2015年全澳肿瘤性肾切除后肾脏替代治疗率翻倍。

要点

  • 肾癌术后ESKD发生率4.9/1000人年,根治性肾切除3年累积发生率1.9%。
  • 部分肾切除3年累积发生率1.0%,低于根治性肾切除。
  • 高龄、男性、术前糖尿病、ASA≥3级、术后住院≥6天与ESKD风险升高相关。

核心结论

  • 在昆士兰2009至2014年间,根治性肾切除患者中每53例有1例在术后3年内发生ESKD,部分肾切除患者中每100例有1例发生ESKD。

研究设计与样本

  • 采用多变量Cox比例风险模型识别与ESKD相关的因素,并对全澳人群数据进行描述性分析。

主要发现

  • 全部患者ESKD发生率为4.9(95%CI 3.9-6.2)/1000人年,3年累积发生率在全部患者、根治性肾切除和部分肾切除中分别为1.7%、1.9%和1.0%。
  • 与ESKD风险增加相关的暴露包括年龄≥65岁(aHR 2.0,95%CI 1.2-3.2)、男性(aHR 2.3,95%CI 1.3-4.3)、术前糖尿病(aHR 1.8,95%CI 1.0-3.3)、ASA≥3级(aHR 4.0,95%CI 2.2-7.4)、社会经济劣势(aHR 1.6,95%CI 0.9-2.7)和术后住院≥6天(aHR 2.1,95%CI 1.4-3.0)。
  • 全澳趋势显示,1995至2015年间肿瘤性肾切除后肾脏替代治疗率从0.3/10万/年增至0.6/10万/年,翻了一倍。

临床怎么用

  • 肾癌术前应评估ESKD风险因素,尤其对高龄、男性、糖尿病、ASA≥3级及术后住院时间长的患者加强肾功能监测。

局限性

  • ESKD通过ICD-10编码住院行政数据识别,可能存在编码不准确或遗漏。
  • 研究为观察性设计,无法确定因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: We investigated the incidence of ESKD after surgical management of kidney cancer in the Australian state of Queensland, and described patterns in the initiation of kidney replacement therapy resulting from kidney cancer across Australia. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: All newly diagnosed cases of kidney cancer in the Australian state of Queensland between January of 2009 and December of 2014 were ascertained through the Queensland Cancer Registry. There were 2739 patients included in our analysis. Patients who developed ESKD were identified using international classification of disease-10-coded hospital administrative data. Incidence rate and 3-year cumulative incidence were calculated, and multivariable Cox proportional hazards models were used to identify factors associated with ESKD. Additional descriptive analysis was undertaken of Australian population data. RESULTS: The incidence rate of ESKD in all patients was 4.9 (95% confidence interval [95% CI], 3.9 to 6.2) per 1000 patient-years. The 3-year cumulative incidence was 1.7%, 1.9%, and 1.0% for all patients, and patients managed with radical or partial nephrectomy, respectively. Apart from preoperative kidney disease, exposures associated with increased ESKD risk were age≥65 years (adjusted hazard ratio [aHR], 2.0; 95% CI, 1.2 to 3.2), male sex (aHR, 2.3; 95% CI, 1.3 to 4.3), preoperative diabetes (aHR, 1.8; 95% CI, 1.0 to 3.3), American Society of Anesthesiologists classification ≥3 (aHR, 4.0; 95% CI, 2.2 to 7.4), socioeconomic disadvantage (aHR, 1.6; 95% CI, 0.9 to 2.7), and postoperative length of hospitalization ≥6 days (aHR, 2.1; 95% CI, 1.4 to 3.0). Australia-wide trends indicate that the rate of kidney replacement therapy after oncologic nephrectomy doubled between 1995 and 2015, from 0.3 to 0.6 per 100,000 per year. CONCLUSIONS: In Queensland between 2009 and 2014, one in 53 patients managed with radical nephrectomy and one in 100 patients managed with partial nephrectomy developed ESKD within 3 years of surgery. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_09_28_CJASNPodcast_18_1_.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Ellis RJ, Edey DP, Del Vecchio SJ, et al. End-Stage Kidney Disease following Surgical Management of Kidney Cancer. Clin J Am Soc Nephrol. 2018. PMID: 30266837. doi:10.2215/CJN.06560518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。